切换至 "中华医学电子期刊资源库"
高级检索
中华胸部外科电子杂志

中华胸部外科电子杂志 ›› 2018, Vol. 05 ›› Issue (02) : 107 -112. doi: 10.3877/cma.j.issn.2095-8773.2018.02.08

所属专题： 文献；

论著

胸腺瘤的外科治疗和预后分析
朱晓磊1, 朱自江2,†(), 庞瑶2, 王文昊2, 脱广鑫2   
  1. 1. 730000　兰州，甘肃中医药大学临床医学院；甘肃省人民医院胸外科
    2. 甘肃省人民医院胸外科
  • 收稿日期:2017-12-15 出版日期:2018-05-28
  • 通信作者: 朱自江

Surgical treatment and prognostic analysis of thymoma

Xiaolei Zhu1, Zijiang Zhu2,†(), Yao Pang2, Wenhao Wang2, Guangxin Tuo2   

  1. 1. School of Clinical Medicine, Gansu University of Chinese Medicine; Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou 730000, China
    2. Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou 730000, China
  • Received:2017-12-15 Published:2018-05-28
  • Corresponding author: Zijiang Zhu
  • About author:
    Corresponding author: Zhu Zijiang, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

朱晓磊, 朱自江, 庞瑶, 王文昊, 脱广鑫. 胸腺瘤的外科治疗和预后分析[J/OL]. 中华胸部外科电子杂志, 2018, 05(02): 107-112.

Xiaolei Zhu, Zijiang Zhu, Yao Pang, Wenhao Wang, Guangxin Tuo. Surgical treatment and prognostic analysis of thymoma[J/OL]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2018, 05(02): 107-112.

目的

探讨外科治疗在胸腺瘤治疗中的作用及预后的影响因素。

方法

回顾性分析2004年1月—2017年1月就诊于甘肃省人民医院胸外科并接受手术治疗的55例胸腺瘤患者的临床资料。生存率的计算及单因素生存分析采用Kaplan-Meier法进行，组间差异使用Log-rank检验进行计算，所有经单因素生存分析有意义的参数均纳入多因素生存，采用Cox分析确定与预后相关的因素。

结果

55例胸腺瘤患者中，成功随访53例，失访2例。53例患者均接受手术治疗，中位随访时间75.3个月，1、3、5、10年生存率分别为71.1%、56.7%、39.3%和23.3%。单因素分析结果显示：临床症状、肿瘤直径、肿瘤切除范围、Masaoka分期、WHO组织学分类及放化疗对胸腺瘤患者术后长期生存率均有显著影响(P<0.01)；多因素Cox分析表明肿瘤切除方式(HR＝5.15，95% CI：1.573～16.883，P<0.05)、肿瘤直径(HR＝5.53，95% CI：1.879～11.797，P<0.05)、WHO分型(HR＝13.23，95% CI：3.015～29.230，P<0.05)、Masaoka分期(HR＝5.18，95%CI：1.597～13.737，P<0.05)以及放化疗(HR＝12.14，95% CI：2.979～49.503，P<0.05)是影响胸腺瘤术后生存率的独立因素。

结论

肿瘤直径、肿瘤切除方式、WHO分型、Masaoka分期以及术后放化疗是影响胸腺瘤患者预后的独立因素。

关键词: 胸腺瘤, 肿瘤直径, 肿瘤切除方式, WHO分型, Masaoka分期, 放疗, 化疗
Objective

To explore the prognostic factors affecting the long-term survival of patients with thymoma.

Methods

The clinical data of 55 patients with thymoma who were treated with thoracic surgery in Gansu Provincial People's Hospital from January 2004 to January 2017 were retrospectively analyzed. The possible prognostic factors were analyzed by univariate analysis and multivariate analysis with Kaplan-Meier method and Cox proportional hazard model, respectively.

Results

Two cases were lost and 53 cases were followed up successfully. All 53 patients underwent surgery. All patients were followed up for 1 to 125 months, and the 1, 3, 5, 10 year survival rates were 71.1%, 56.7%, 39.3% and 23.3% respectively. The significant prognostic factors demonstrated by univariate analysis included age, clinical symptoms, tumor diameter, Masaoka staging, WHO histologic classification, completeness of resection, and chemoradiotherapy (P<0.01). According to multivariate analysis, the tumor type (HR=5.15, 95% CI: 1.573-16.883, P<0.05), tumor diameter (HR=5.53, 95% CI: 1.879-11.797, P<0.05), WHO classification (HR=13.23, 95% CI: 3.015-29.230, P<0.05), Masaoka staging (HR=5.18, 95% CI: 1.597-13.737, P<0.05) and chemoradiotherapy (HR=12.14, 95% CI: 2.979-49.503, P<0.05) are independent factors affecting the postoperative survival rate of thymoma.

Conclusions

Tumor diameter, tumor resection, WHO classification, Masaoka and postoperative chemoradiotherapy were independent prognostic factors.

Key words: Thymoma, Tumor diameter, Tumor resection, WHO classification, Masaoka staging, Radiotherapy, Chemotherapy
图1 53例胸腺瘤患者术后预后单因素分析。A.有无临床症状；B.肿瘤直径；C.切除方式；D.WHO分型；E. Masaoka分期；F.术后放化疗
表1 影响恶性胸腺瘤患者预后的单因素分析
性别 1年生存率(%) 3年生存率(%) 5年生存率(%) 10年生存率(%) χ2值 P值
性别 ? ? ? ? 0.02 0.991
? 男性(n＝33) 96.8 87.8 75.8 45.8 ? ?
? 女性(n＝20) 97.6 85.7 76.2 47.6 ? ?
年龄 ? ? ? ? 5.04 0.543
? <30岁(n＝7) 85.7 71.4 61.4 42.9 ? ?
? 30～60岁(n＝36) 97.2 88.9 67.7 44.4 ? ?
? >60岁(n＝10) 89.0 79.9 70.0 40.0 ? ?
有无症状 ? ? ? ? 13.23 0.004
? 有(n＝33) 96.9 78.7 42.4 18.1 ? ?
? 无(n＝20) 100.0 95.0 90.0 78.0 ? ?
肿瘤直径 ? ? ? ? 7.748 0.021
? <5 cm(n＝13) 92.3 92.3 76.9 4.1 ? ?
? 5～10 cm(n＝27) 96.2 85.1 74.0 40.7 ? ?
? >10 cm 92.3 76.9 15.3 7.6 ? ?
肿瘤切除范围 ? ? ? ? 15.75 0.015
? R0(n＝23) 100.0 95.6 91.3 78.2 ? ?
? R1(n＝16) 87.5 75.0 43.7 7.1 ? ?
? R2(n＝14) 71.4 50 28.5 7.1 ? ?
WHO分型 ? ? ? ? 25.69 0.041
? A型(n＝11) 100.0 100.0 90.1 72.7 ? ?
? AB型(n＝13) 100.0 92.3 76.9 61.5 ? ?
? B1型(n＝6) 100.0 83.3 50.0 16.6 ? ?
? B2型(n＝9) 100.0 88.8 55.5 11，.1 ? ?
? B3型(n＝5) 80.0 75.0 40.0 0.00 ? ?
? C型(n＝9) 78.5 55.5 22.2 0.00 ? ?
Masaoka分期 ? ? ? ? 16.18 <0.001
? Ⅰ期(n＝9) 100.0 100.0 88.9 66.7 ? ?
? Ⅱ期(n＝20) 95.0 95.0 85.0 55.0 ? ?
? Ⅲ期(n＝16) 93.7 87.5 43.7 6.2 ? ?
? Ⅳ期(n＝8) 75.0 25.0 0.00 0.00 ? ?
术后放化疗 ? ? ? ? 31.81 0.001
? 是(n＝30) 93.3 78.5 40.0 20.0 ? ?
? 否(n＝23) 95.6 91.3 82.6 47.8 ? ?
表2 影响恶性胸腺瘤患者预后的多因素分析
因素 β值 Wald值 HR 95%CI P值
切除方式 1.639 7.260 5.153 (1.57～16.88) 0.007
有无症状 1.361 3.123 1.263 (0.71～3.51) 0.254
肿瘤直径 1.793 8.603 5.532 (1.87～11.79) 0.003
WHO组织学分类 2.975 14.253 13.234 (3.01～29.23) <0.001
Masaoka分期 1.645 10.852 5.185 (1.95～13.73) <0.001
放化疗 2.496 12.005 12.144 (2.97～49.50) 0.005
1
Maury J M, Girard N, Tabutin M, et al. Intra-Thoracic Chemo-Hyperthermia for pleural recurrence of thymoma[J]. Lung Cancer, 2017, 108: 1-6.
2
Jansen A, van Deuren M, Miller J, et al. Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective[J]. Clin Immunol, 2016, 171: 12-17.
3
Vachlas K, Zisis C, Rontogianni D, et al. Thymoma and myasthenia gravis: clinical aspects and prognosis[J]. Asian Cardiovasc Thorac Ann , 2012, 20(1): 48-52.
4
Yan TD, Black D, Bannon PG, et al. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer.[J]. J Clin Oncol，2009, 27(15):2553-2562.
5
Okumura M, Utsumi T. Treatment strategy for thymoma and thymic carcinoma[J]. Kyobu Geka，2011, 64(8 Suppl): 719-724.
6
Basse C, du Vignaux C M, Girard N. Postoperative radiotherapy in completely resected stage Ⅱ and Ⅲ thymoma: how to translate the potential survival benefit in the setting of the future adoption of the IASLC-ITMIG TNM-based staging system[J]. J Thorac Oncol, 2017, 12(1): e8-e9.
7
Fukui T, Yokoi K. New TNM staging system for thymic malignancies[J]. Gan To Kagaku Ryoho, 2016, 43(5): 518-522..
8
Singh G, Rumende CM, Amin Z. Thymoma: diagnosis and treatment[J]. Acta Med Indones, 2011, 43(1): 74-78.
9
Rimner A, Yao X, Huang J, et al. Postoperative radiation therapy is associated with longer overall survival in completely resected stage Ⅱ and Ⅲ thymoma—an analysis of the International Thymic Malignancies Interest Group retrospective database[J]. J Thorac Oncol, 2016, 11(10): 1785-1792.
10
Shinya T, Tanaka T, Soh J, et al. Diagnostic value of dual-time-point F-18 FDG PET/CT and chest CT for the prediction of thymic epithelial neoplasms[J]．Acta Med Okayama, 2017, 71(2): 105-112.
11
Gubens MA. Treatment updates in advanced thymoma and thymic carcinoma[J]. Curr Treat Options Oncol, 2012, 13(4): 527-534.
12
Wei ML, Gu L, Kang D, et al. Chemotherapy for thymic carcinoma and advanced thymoma in adults[J]. Cochrane Database Syst Rev, 2013, 8(8):1-7.
13
Detterbeck FC, Stratton K, Giroux D, et al. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors[J]. J Thorac Oncol，2014, 9(9): S65-S72
14
Kamel M, Narula N, Port JL, et al. PS01. 26: Prognostic value of the new WHO thymoma classification: single institution cross validation study[J]. J Thorac Oncol, 2016, 11(11): S284-S285.
15
Zhang Z, Cui Y, Jia R, et al. Myasthenia gravis in patients with thymoma affects survival rate following extended thymectomy[J]. Oncol Lett, 2016, 11(6): 4177-4182.
16
Tseng YL, Chang JM, Lai WW, et al. Behind and beyond the Masaoka staging: a 25-year follow-up study of tumor recurrence in cCompletely resected thymic epithelial tumors in a single institution[J]. Medicine, 2015, 94(52):3542-3547.
17
Lee GD, Kim HR, Choi SH, et al. Prognostic stratification of thymic epithelial tumors based on both Masaoka-Koga stage and WHO classification systems[J]. J Thorac Dis, 2016, 8(5): 901-908.
18
Di Crescenzo VG, Napolitano F, Panico C, et al. Surgical approach in thymectomy: Our experience and review of the literature[J]．Int J Surg Case Rep, 2017, 39: 19-24
19
Banna GL, Sheel A, Sheel V, et al. Treatment and prognostic factors of patients with thymic epithelial tumors at first recurrence or progression[J]. Future Oncol, 2017, 13(27): 2429-2439.
20
Lombe DC, Jeremic B. A review of the place and role of radiotherapy in thymoma[J]. Clin Lung Cancer, 2015, 16(6): 406-412.
21．
Giannopoulou A, Gkiozos I, Harrington KJ, et al. Thymoma and radiation therapy: a systematic review of medical treatment[J]. Expert Rev Anticancer Ther, 2013, 13(6): 759-766.
22
Ma J, Sun X, Huang L, et al. Postoperative radiotherapy and tumor recurrence after complete resection of stage Ⅱ/Ⅲ thymic tumor: a meta-analysis of cohort studies[J]. Onco Targets Ther, 2016, 9: 4517-4526.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(06): 571-579.
[2] 王聪, 李云涛, 唐甜甜, 王鑫蕊, 吕鑫, 范志刚. 多基因检测对激素受体阳性、HER-2阴性乳腺癌新辅助化疗疗效预测的研究进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 292-296.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[6] 薛庆, 施赛叶, 徐雅文, 盛夏, 张芹芹. 追踪方法学联合失效模式与效应分析在膀胱灌注化疗患者中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 553-559.
[7] 张昊, 潘卫东. 胰腺癌新辅助化疗后可切除性评估现状及进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 629-633.
[8] 中国抗癌协会, 中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-肛管癌（2024 版）[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 441-449.
[9] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10] 石阳, 于剑锋, 曹可, 翟志伟, 叶春祥, 王振军, 韩加刚. 可扩张金属支架置入联合新辅助化疗治疗完全梗阻性左半结肠癌围手术期并发症分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 464-471.
[11] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[12] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[13] 张颖, 赵鑫, 陈佳梅, 李雁. 术前化疗对CRS+HIPEC 治疗腹膜假黏液瘤预后影响的meta 分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 826-835.
[14] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
[15] 张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号